Cancer Research and Treatment

Original Articles

Prevalence and Predictors of Sustained Smoking after a Cancer Diagnosis in Korean Men: Hye Yeon Koo, Kiheon Lee, Sang Min Park, Jooyoung Chang, Kyuwoong Kim, Seulggie Choi, Mi Hee Cho, Jihye Jun, Sung Min Kim; Cancer Res Treat. 2020;52(1):139-148. Published online June 25, 2019; DOI: https://doi.org/10.4143/crt.2018.609

Purpose
Although smoking has a significant impact on mortality and morbidity of cancer patients, many patients continue to smoke post-diagnosis. The purpose of this study was to investigate prevalence and predictors of sustained smoking among male cancer survivors.
Materials and Methods
The Korean National Health Insurance Service-National Health Screening Cohort database was used for this population-based, retrospective study. Study subjects were 15,141 men who were diagnosed with their first incident cancer between 2004 and 2011. Changes in smoking status before and after a cancer diagnosis were investigated. For patients who were current smokers pre-diagnosis, association between post-diagnosis sustained smoking and demographic, socioeconomic, and clinical variables were examined.
Results
Of the 4,657 pre-diagnosis smokers, 2,255 (48%) had quit after cancer diagnosis, while 2,402 (51.6%) continued to smoke. In a multivariate logistic regression analysis, younger age at cancer diagnosis (adjusted odds ratio [aOR], 1.37; 95% confidence interval [CI], 1.21 to 1.55; p < 0.001), low socioeconomic status (aOR, 1.29; 95% CI, 1.15 to 1.45; p ≤ 0.001), pre-diagnosis heavy smoking (aOR, 1.24; 95% CI, 1.09 to 1.41; p=0.001), diagnosis of non-smoking– related cancer (aOR, 1.67; 95% CI, 1.42 to 1.96; p < 0.001), and high serum glucose level (aOR, 1.23; 95% CI, 1.03 to 1.46; p=0.019) were associated with sustained smoking after a cancer diagnosis.
Conclusion
Almost half of the male smokers continue to smoke after a cancer diagnosis. Targeted interventions for smoking cessation should be considered for patients with younger age, low socioeconomic status, heavy smoking history, non-smoking–related cancer, and high blood glucose levels.

Citations

Citations to this article as recorded by

A comparative study of health behaviors in adult male cancer survivors and the general male population in Korea: from the Korea national health and nutrition examination survey VII-VIII (2016–2021)
Hyein Jung, Yoonjoo Choi, Byungmi Kim
Supportive Care in Cancer.2025;[Epub] CrossRef
Effects of smoking cessation on taste function in heavy smokers undergoing hemiglossectomy for tongue squamous cell carcinoma
Paolo Boscolo-Rizzo, Thomas Hummel, Alberto Vito Marcuzzo, Antonino Maniaci, Giacomo Spinato, Luca Raimondo, Luigi Angelo Vaira, Rachele Tulissi, Anna Menini, Franco Trabalzini, Enzo Emanuelli, Vittorio Grill, Jerry Polesel, Fabiola Giudici, Giancarlo Tir
European Archives of Oto-Rhino-Laryngology.2025; 282(10): 5315. CrossRef
Smoking behavior changes and risk of cardiovascular diseases after cancer diagnosis: a nationwide cohort study
In Young Cho, Jinhyung Jung, Wonyoung Jung, Mi Hee Cho, Hye Yeon Koo, Kyungdo Han, Dong Wook Shin
Supportive Care in Cancer.2025;[Epub] CrossRef
Prevalence of Current Cigarette Smoking by Sociodemographic Characteristics in U.S. Cancer Survivors
Liza M. González Ruiz, Lía I. Mondragón Márquez, Daniela L. Domínguez Bueso, Jason J. Liu
Substance Use & Misuse.2024; 59(4): 486. CrossRef
Healthy lifestyle and cancer survival: A multinational cohort study
Zilong Bian, Rongqi Zhang, Shuai Yuan, Rong Fan, Lijuan Wang, Susanna C. Larsson, Evropi Theodoratou, Yimin Zhu, Shouling Wu, Yuan Ding, Xue Li
International Journal of Cancer.2024; 154(10): 1709. CrossRef
Smoking Cessation Support: A Marathon, Not a Sprint; The Perspectives of Cancer Patients Who Smoke
Patricia Fox, Nancy Bhardwaj, Ailsa Lyons, Vikram Niranjan, Kate Frazer, Shiraz Syed, Amanda McCann, Sinead Brennan, Donal Brennan, Catherine Kelly, Michael Keane, Patricia Fitzpatrick
Seminars in Oncology Nursing.2024; 40(2): 151584. CrossRef
Association Between Cardiovascular Event Type and Smoking Cessation Rates Among Outpatients With Atherosclerotic Cardiovascular Disease: Insights From the NCDR PINNACLE Registry
Vittal Hejjaji, Edward F. Ellerbeck, Philip G. Jones, Christina M. Pacheco, Ali O. Malik, Paul S. Chan, John A. Spertus, Suzanne V. Arnold
Circulation: Cardiovascular Quality and Outcomes.2024;[Epub] CrossRef
Determinants of persistent smoking among breast cancer survivors
Kathleen Gali, Sita Aryal, Frederike Bokemeyer, Sabine Behrens, Petra Seibold, Nadia Obi, Heiko Becher, Jenny Chang-Claude
Preventive Medicine Reports.2024; 48: 102913. CrossRef
Factors associated with successful smoking cessation in men with or without cardiovascular disease or cancer: Nationwide Korean population analysis
Youngmee Kim, Won-Kyung Cho
Tobacco Induced Diseases.2023; 21(February): 1. CrossRef
Mortality risk according to smoking trajectories after cancer diagnosis among Korean male cancer survivors: A population-based cohort study
Thi Tra Bui, Minji Han, Ngoc Minh Luu, Thi Phuong Thao Tran, Sun Young Kim, Young Ae Kim, Min Kyung Lim, Jin-Kyoung Oh
Tobacco Induced Diseases.2023; 21(May): 1. CrossRef
Challenges posed by COVID‐19 in cancer patients: A narrative review
Zeinab Mohseni Afshar, Rezvan Hosseinzadeh, Mohammad Barary, Soheil Ebrahimpour, Amirmasoud Alijanpour, Babak Sayad, Dariush Hosseinzadeh, Seyed Rouhollah Miri, Terence T. Sio, Mark J. M. Sullman, Kristin Carson‐Chahhoud, Arefeh Babazadeh
Cancer Medicine.2022; 11(4): 1119. CrossRef
Quitting Smoking At or Around Diagnosis Improves the Overall Survival of Lung Cancer Patients: A Systematic Review and Meta-Analysis
Saverio Caini, Marco Del Riccio, Virginia Vettori, Vieri Scotti, Chiara Martinoli, Sara Raimondi, Giulio Cammarata, Domenico Palli, Marco Banini, Giovanna Masala, Sara Gandini
Journal of Thoracic Oncology.2022; 17(5): 623. CrossRef
Cessation experiences and quitting perspectives of Jordanian cancer patients who smoke
Feras I. Hawari, Minas A. Abu Alhalawa, Rasha H. Alshrideh, Ahmad M. Al Nawaiseh, Alia Khamis, Yasmeen I. Dodin, Nour A. Obeidat
Cancer Epidemiology.2022; 79: 102207. CrossRef
Changes in cigarette smoking behavior among breast cancer and unaffected women – A prospective study in the MARIE cohort
Kathleen Gali, Frederike Bokemeyer, Sabine Behrens, Annika Möhl, Nadia Obi, Heiko Becher, Jenny Chang-Claude
Cancer Epidemiology.2022; 81: 102282. CrossRef
Supporting Smokers in Difficult Settings: Suggestions for Better Education and Counseling in Cancer Centers in Jordan
Feras I. Hawari, Minas A. Abu Alhalawa, Rasha H. Alshraiedeh, Ahmad M. Al Nawaiseh, Alia Khamis, Yasmeen I. Dodin, Nour A. Obeidat
Current Oncology.2022; 29(12): 9335. CrossRef
Efficacy of an inpatient smoking cessation program at a single regional cancer center
Ha-Young Park, Yu-Ri Choe, In-Jae Oh, Min-Seok Kim, Bo Gun Kho, Hong-Joon Shin, Cheol Kyu Park, Yu-Il Kim, Young-Chul Kim, Hye-Ran Ahn, Sun-Seog Kweon
Medicine.2021; 100(6): e24745. CrossRef
Smoking Cessation in Cancer Survivors
Young Gyu Cho
Korean Journal of Family Medicine.2021; 42(4): 258. CrossRef
Impact of Family and Social Network on Tobacco Cessation Amongst Cancer Patients
Melissa Neumann, Neal Murphy, Nagashree Seetharamu
Cancer Control.2021;[Epub] CrossRef

8,114 View
193 Download
18 Web of Science
18 Crossref

Effect of Smoking Cessation and Reduction on the Risk of Cancer in Korean Men: A Population Based Study: Seulggie Choi, Jooyoung Chang, Kyuwoong Kim, Sang Min Park, Kiheon Lee; Cancer Res Treat. 2018;50(4):1114-1120. Published online November 24, 2017; DOI: https://doi.org/10.4143/crt.2017.326

Abstract PDF Supplementary Material PubReader ePub

Purpose
The purpose of this study was to investigate the effect of smoking habit change on the risk of cancer.
Materials and Methods
From the Korean National Health Insurance Service database, we determined the change in smoking habit between the first (2002 and 2003) and second (2004 and 2005) health examination periods. A total of 143,071 men were categorized into baseline heavy (≥ 20 cigarettes per day), moderate (10-19 cigarettes per day), light (< 10 cigarettes per day) smokers, quitters, and never smokers, after which the change in smoking status was determined during the second health examination. The participants were then followed up from 2006 to 2013 for all cancer, smoking related cancer, and lung cancer.
Results
Compared to heavy continual smokers, heavy smokers who quit had reduced risk of smoking related cancer (hazard ratio [HR], 0.74; 95% confidence interval [CI], 0.56 to 0.97) and tended to have reduced risk of all cancer (HR, 0.87; 95% CI, 0.75 to 1.00). Moderate smokers who reduced the amount of smoking to light levels had decreased risk of all cancer (HR, 0.82; 95% CI, 0.72 to 0.94), smoking related cancer (HR, 0.74; 95% CI, 0.59 to 0.93), and lung cancer (HR, 0.55; 95% CI, 0.38 to 0.79) compared to heavy continual smokers.
Conclusion
Smoking reduction decreases the risk of all cancer, smoking related cancer, and lung cancer. While smoking cessation should be the treatment of choice for smokers, smoking reduction may serve as an alternative strategy for those who cannot quit.

Citations

Citations to this article as recorded by

Smoking cessation is a protective factor for lung cancer onset and mortality: a population-based prospective cohort study
Wei Yin, Zhuochen Lin, Wei-Jie Gong, Wen-Xuan Wang, Ying-Ying Zhu, Yi-Lin Fu, Han Yang, Jin-Xin Zhang, Peng Lin, Ji-Bin Li
BMC Cancer.2025;[Epub] CrossRef
Effect of smoking cessation on new-onset diabetes mellitus in dyslipidemic individuals: A population-based cohort study
Wooin Seo, Se Young Jung, KeeHyuck Lee, Woo Kyung Bae, Jong Soo Han, Hyejin Lee, Ji Soo Kim, Hye Yeon Koo, Seung Yeon Lee, Kiheon Lee
Tobacco Induced Diseases.2025; 23(June): 1. CrossRef
Cancer Risk Following Smoking Cessation in Korea
Eunjung Park, Hee-Yeon Kang, Min Kyung Lim, Byungmi Kim, Jin-Kyoung Oh
JAMA Network Open.2024; 7(2): e2354958. CrossRef
Impact of smoking reduction on lung cancer risk in patients with COPD who smoked fewer than 30 pack-years: a nationwide population-based cohort study
Sun Hye Shin, Taeyun Kim, Hyunsoo Kim, Juhee Cho, Danbee Kang, Hye Yun Park
Respiratory Research.2024;[Epub] CrossRef
Changes in smoking use and subsequent lung cancer risk in the Alpha-Tocopherol, Beta-Carotene Cancer Prevention Study
Daniela S Gutiérrez-Torres, Sungduk Kim, Demetrius Albanes, Stephanie J Weinstein, Maki Inoue-Choi, Paul S Albert, Neal D Freedman
JNCI: Journal of the National Cancer Institute.2024; 116(6): 895. CrossRef
Global epidemiology of early‐onset upper gastrointestinal cancer: trend from the Global Burden of Disease Study 2019
Pojsakorn Danpanichkul, Thanida Auttapracha, Siwanart Kongarin, Ben Ponvilawan, Daniel M. Simadibrata, Kwanjit Duangsonk, Supitchaya Jaruvattanadilok, Sakditad Saowapa, Kanokphong Suparan, Rashid N. Lui, Suthat Liangpunsakul, Michael B. Wallace, Karn Wija
Journal of Gastroenterology and Hepatology.2024; 39(9): 1856. CrossRef
Smoking cessation rate and predictors of successful quitting in Jordan: A cross-sectional study
Nuha W. Qasem, Batool H. Al-Omoush, Sami K. Altbeinat, Moutasem M. Al-Dlaijem, Reham I. Salahat, Samer A. Okour
Medicine.2024; 103(27): e38708. CrossRef
Smoking-attributable Mortality in Korea, 2020: A Meta-analysis of 4 Databases
Eunsil Cheon, Yeun Soo Yang, Suyoung Jo, Jieun Hwang, Keum Ji Jung, Sunmi Lee, Seong Yong Park, Kyoungin Na, Soyeon Kim, Sun Ha Jee, Sung-il Cho
Journal of Preventive Medicine and Public Health.2024; 57(4): 327. CrossRef
Passive smoking and risk of pancreatic cancer: an updated systematic review and meta-analysis
Xudong Wang, Zihan Wang, Xujie Wang
PeerJ.2024; 12: e18017. CrossRef
Body mass index, waist circumference and cardiovascular diseases in transitional ages (40 and 66 years)
Jung Eun Yoo, Kyungdo Han, Jin‐Hyung Jung, Yang‐Im Hur, Yang Hyun Kim, Eun Sook Kim, Jang Won Son, Eun‐Jung Rhee, Won‐Young Lee, Ga Eun Nam
Journal of Cachexia, Sarcopenia and Muscle.2023; 14(1): 369. CrossRef
Latency period of aristolochic acid-induced upper urinary tract urothelial carcinoma
Jing-Rong Jhuang, Po-Chun Chiu, Tung-Che Hsieh, Chung-Hsin Chen, Yeong-Shiau Pu, Wen-Chung Lee
Frontiers in Public Health.2023;[Epub] CrossRef
Association between smoking and obstructive sleep apnea based on the STOP-Bang index
Yun Seo Jang, Nataliya Nerobkova, Kyungduk Hurh, Eun-Cheol Park, Jaeyong Shin
Scientific Reports.2023;[Epub] CrossRef
The effects of smoking habit change on the risk of depression–Analysis of data from the Korean National Health Insurance Service
Ga Eun Kim, Min-ho Kim, Weon-Jeon Lim, Soo In Kim
Journal of Affective Disorders.2022; 302: 293. CrossRef
Effect of smoking reduction, cessation, and resumption on cancer risk: A nationwide cohort study
Jung Eun Yoo, Kyungdo Han, Dong Wook Shin, Wonyoung Jung, Dahye Kim, Cheol Min Lee, Hyuktae Kwon, Kyu‐Won Jung, Yun‐Mi Song
Cancer.2022; 128(11): 2126. CrossRef
Psychosocial stress and cancer risk: a narrative review
Ananyaa Mohan, Inge Huybrechts, Nathalie Michels
European Journal of Cancer Prevention.2022; 31(6): 585. CrossRef
Smoking trajectory and cancer risk: A population-based cohort study
Minh Luu, Minji Han, Tra Bui, Phuong Thao Tran, Min-Kyung Lim, Jin Oh
Tobacco Induced Diseases.2022; 20(August): 1. CrossRef
Longitudinal Changes in Smoking Habits in Women and Subsequent Risk of Cancer
Thi Xuan Mai Tran, Soyeoun Kim, Huiyeon Song, Boyoung Park
American Journal of Preventive Medicine.2022; 63(6): 894. CrossRef
Health promotion: the essence of primary healthcare
Sung Sunwoo
Journal of the Korean Medical Association.2022; 65(12): 772. CrossRef
Cigarette Smoking Reduction and Health Risks: A Systematic Review and Meta-analysis
Joanne T Chang, Gabriella M Anic, Brian L Rostron, Manju Tanwar, Cindy M Chang
Nicotine & Tobacco Research.2021; 23(4): 635. CrossRef
Decreased Levels of Soluble CD44 in a High-Risk Population following a Smoking Cessation Program
Drew H. Smith, Shahm Raslan, Isildinha M. Reis, Abdurrahman Al-Awady, Isabella Buitron, Melanie Perez, Huaping Liu, Jerri Halgowich, Claudia Gordon, Monica Webb Hooper, Noël C. Barengo, Elizabeth J. Franzmann
International Journal of Environmental Research and Public Health.2021; 18(24): 13174. CrossRef
Exposure to oral bisphosphonates and risk of gastrointestinal cancer
D. Choi, S. Choi, J. Chang, S. M. Park
Osteoporosis International.2020; 31(4): 775. CrossRef
Smoking Cessation Improves the Symptoms and the Findings of Laryngeal Irritation
A. Secil Kayalı Dinc, Melih Cayonu, Tijen Sengezer, M. Melih Sahin
Ear, Nose & Throat Journal.2020; 99(2): 124. CrossRef
Association between Post-Diagnosis Particulate Matter Exposure among 5-Year Cancer Survivors and Cardiovascular Disease Risk in Three Metropolitan Areas from South Korea
Seulggie Choi, Kyae Hyung Kim, Kyuwoong Kim, Jooyoung Chang, Sung Min Kim, Seong Rae Kim, Yoosun Cho, Gyeongsil Lee, Joung Sik Son, Sang Min Park
International Journal of Environmental Research and Public Health.2020; 17(8): 2841. CrossRef
Cigarette Smoking Is Associated with Increased Risk of Malignant Gliomas: A Nationwide Population-Based Cohort Study
Stephen Ahn, Kyung-Do Han, Yong-Moon Park, Jung Min Bae, Sang Uk Kim, Sin-Soo Jeun, Seung Ho Yang
Cancers.2020; 12(5): 1343. CrossRef
The Association of Smoking Exposure at Home with Attempts to Quit Smoking and Cessation Success: A Survey of South Korean Adolescents Who Smoke
Wonjeong Jeong, Yun Kyung Kim, Jae Hong Joo, Sung-In Jang, Eun-Cheol Park
International Journal of Environmental Research and Public Health.2020; 17(11): 4129. CrossRef
Exploring smoking cessation behaviors of outpatients in outpatient clinics
Ching-Yi Hsu, Hung-En Liao, Li-Chun Huang
Medicine.2020; 99(27): e20971. CrossRef
UegWeek 2020 Poster Presentations

United European Gastroenterology Journal.2020; 8(S8): 144. CrossRef
Assessing the lung cancer risk reduction potential of candidate modified risk tobacco products
Julia Hoeng, Serge Maeder, Patrick Vanscheeuwijck, Manuel C. Peitsch
Internal and Emergency Medicine.2019; 14(6): 821. CrossRef
Prevalence of tobacco related chronic diseases and its role in smoking cessation among smokers in a rural area of Shanghai, China: a cross sectional study
Ruiping Wang, Yonggen Jiang, Chunxia Yao, Meiying Zhu, Qi Zhao, Limei Huang, Guimin Wang, Ying Guan, Engelgau Michael, Genming Zhao
BMC Public Health.2019;[Epub] CrossRef
Relationships between smoking duration, smoking intensity, hypothetical tobacco price increases, and smoking habit change intention among current smokers in Shanghai
Ruiping Wang, Yonggen Jiang, Xin Li, Qi Zhao, Meiying Zhu, Ying Guan, Genming Zhao
Journal of International Medical Research.2019; 47(10): 5216. CrossRef
The impact of smoking cessation attempts on stress levels
Seong-Jun Kim, Wonjeong Chae, Woo-Hyun Park, Min-Ho Park, Eun-Cheol Park, Sung-In Jang
BMC Public Health.2019;[Epub] CrossRef
Cancer risk among young men with weight gain after smoking cessation: A population-based cohort study
Kyuwoong Kim, Seulggie Choi, Gyeongsil Lee, Su-Min Jeong, Sung Min Kim, Joung Sik Son, Jae-Moon Yun, Yeon-Yong Kim, Seong Yong Park, Sang Min Park
Cancer Epidemiology.2019; 60: 86. CrossRef

11,169 View
312 Download
33 Web of Science
32 Crossref

Sub-classification of Advanced-Stage Hepatocellular Carcinoma: A Cohort Study Including 612 Patients Treated with Sorafenib: Jeong-Ju Yoo, Goh Eun Chung, Jeong-Hoon Lee, Joon Yeul Nam, Young Chang, Jeong Min Lee, Dong Ho Lee, Hwi Young Kim, Eun Ju Cho, Su Jong Yu, Yoon Jun Kim, Jung-Hwan Yoon, Seoul Liver Group; Cancer Res Treat. 2018;50(2):366-373. Published online May 15, 2017; DOI: https://doi.org/10.4143/crt.2017.126

Abstract PDF PubReader ePub

Purpose
Advanced hepatocellular carcinoma (HCC) is associated with various clinical conditions including major vessel invasion, metastasis, and poor performance status. The aim of this study was to establish a prognostic scoring system and to propose a sub-classification of the Barcelona-Clinic Liver Cancer (BCLC) stage C.
Materials and Methods
This retrospective study included consecutive patientswho received sorafenib for BCLC stage C HCC at a single tertiary hospital in Korea. A Cox proportional hazard model was used to develop a scoring system, and internal validationwas performed by a 5-fold cross-validation. The performance of the model in predicting risk was assessed by the area under the curve and the Hosmer-Lemeshow test.
Results
A total of 612 BCLC stage C HCC patients were sub- classified into strata depending on their performance status. Five independent prognostic factors (Child-Pugh score, α-fetoprotein, tumor type, extrahepatic metastasis, and portal vein invasion) were identified and used in the prognostic scoring system. This scoring system showed good discrimination (area under the receiver operating characteristic curve, 0.734 to 0.818) and calibration functions (both p < 0.05 by the Hosmer-Lemeshow test at 1 month and 12 months, respectively). The differences in survival among the different risk groups classified by the total score were significant (p < 0.001 by the log-rank test in both the Eastern Cooperative Oncology Group 0 and 1 strata).
Conclusion
The heterogeneity of patientswith BCLC stage C HCC requires sub-classification of advanced HCC. A prognostic scoring system with five independent factors is useful in predicting the survival of patients with BCLC stage C HCC.

Citations

Citations to this article as recorded by

Tumor burden affects the progression pattern on the prognosis in patients treated with sorafenib
Jun Sun, Dongdong Xia, Wei Bai, Xiaomei Li, Enxing Wang, ZhanXin Yin, Guohong Han
Frontiers in Oncology.2024;[Epub] CrossRef
A Machine Learning Algorithm Facilitates Prognosis Prediction and Treatment Selection for Barcelona Clinic Liver Cancer Stage C Hepatocellular Carcinoma
Ji W. Han, Soon K. Lee, Jung H. Kwon, Soon W. Nam, Hyun Yang, Si H. Bae, Ji H. Kim, Heechul Nam, Chang W. Kim, Hae L. Lee, Hee Y. Kim, Sung W. Lee, Ahlim Lee, U I. Chang, Do S. Song, Seok-Hwan Kim, Myeong J. Song, Pil S. Sung, Jong Y. Choi, Seung K. Yoon,
Clinical Cancer Research.2024; 30(13): 2812. CrossRef
Subclassification of advanced-stage hepatocellular carcinoma with macrovascular invasion: combined transarterial chemoembolization and radiotherapy as an alternative first-line treatment
Sujin Jin, Won-Mook Choi, Ju Hyun Shim, Danbi Lee, Kang Mo Kim, Young-Suk Lim, Han Chu Lee, Jinhong Jung, Sang Min Yoon, Jonggi Choi
Journal of Liver Cancer.2023; 23(1): 177. CrossRef
Development and validation of web‐based prognostic nomograms for massive hepatocellular carcinoma (≥10 cm): A retrospective study based on the SEER database
Guizhong Huang, Qiaohong Lin, Pengfei Yin, Kai Mao, Jianlong Zhang
Cancer Medicine.2023; 12(12): 13167. CrossRef
Development of a Multivariate Prognostic Model for Lenvatinib Treatment in Hepatocellular Carcinoma
Xiaomi Li, Xiaoyan Ding, Mei Liu, Jingyan Wang, Wei Li, Jinglong Chen
The Oncologist.2023; 28(10): e942. CrossRef
Prognostic models for outcome prediction in patients with advanced hepatocellular carcinoma treated by systemic therapy: a systematic review and critical appraisal
Li Li, Xiaomi Li, Wendong Li, Xiaoyan Ding, Yongchao Zhang, Jinglong Chen, Wei Li
BMC Cancer.2022;[Epub] CrossRef
Identification and validation of a prognostic model of necroptosis-related lncRNAs in hepatocellular carcinoma
Min Chen, Guang-Bo Wu, Shan Hua, Zhi-Feng Zhao, Hong-Jie Li, Meng Luo
Frontiers in Genetics.2022;[Epub] CrossRef
Prognostic value of a nomogram based on peripheral blood immune parameters in unresectable hepatocellular carcinoma after intensity-modulated radiotherapy
Jian-Xu Li, Mei-Ling He, Mo-Qin Qiu, Liu-Ying Yan, Mei-Ying Long, Jian-Hong Zhong, Rui-Jun Zhang, Chun-Feng Liang, Ya-Dan Pang, Jun-Kun He, Qian-Qian Chen, Jin-Xia Weng, Shi-Xiong Liang, Bang-De Xiang
BMC Gastroenterology.2022;[Epub] CrossRef
A Nomogram-Based Prognostic Model for Advanced Hepatocellular Carcinoma Patients Treated with Sorafenib: A Multicenter Study
Giovanni Marasco, Francesco Poggioli, Antonio Colecchia, Giuseppe Cabibbo, Filippo Pelizzaro, Edoardo Giannini, Sara Marinelli, Gian Rapaccini, Eugenio Caturelli, Mariella Di Marco, Elisabetta Biasini, Fabio Marra, Filomena Morisco, Francesco Foschi, Marc
Cancers.2021; 13(11): 2677. CrossRef
Clinical Characteristics of Long-Term Survivors After Sorafenib Treatment for Unresectable Hepatocellular Carcinoma: A Korean National Multicenter Retrospective Cohort Study
Young Youn Cho, Su Jong Yu, Hye Won Lee, Do Young Kim, Wonseok Kang, Yong-Han Paik, Pil Soo Sung, Si Hyun Bae, Su Cheol Park, Young Seok Doh, Kang Mo Kim, Eun Sun Jang, In Hee Kim, Won Kim, Yoon Jun Kim
Journal of Hepatocellular Carcinoma.2021; Volume 8: 613. CrossRef
Identification and Validation of a Prognostic Prediction Model of m6A Regulator-Related LncRNAs in Hepatocellular Carcinoma
Chen Jin, Rui Li, Tuo Deng, Jialiang Li, Yan Yang, Haoqi Li, Kaiyu Chen, Huihua Xiong, Gang Chen, Yi Wang
Frontiers in Molecular Biosciences.2021;[Epub] CrossRef
Construction and validation of an N6‑methyladenosine‑associated prognostic signature in hepatocellular carcinoma
Peng Zhu, Qianqian Ren, Nan He, Cheng Zhou, Qianna Jin, Zhao Gong
Oncology Letters.2021;[Epub] CrossRef
Improved survival prediction and comparison of prognostic models for patients with hepatocellular carcinoma treated with sorafenib
Tim A. Labeur, Sarah Berhane, Julien Edeline, Jean‐Frederic Blanc, Dominik Bettinger, Tim Meyer, Jeroen L. A. Van Vugt, David W. G. Ten Cate, Robert A. De Man, Ferry A. L. M. Eskens, Alessandro Cucchetti, Laura J. Bonnett, Otto M. Van Delden, Heinz‐Josef
Liver International.2020; 40(1): 215. CrossRef
A novel prognostic score model based on combining systemic and hepatic inflammation markers in the prognosis of HBV-associated hepatocellular carcinoma patients
Tingting Zhang, Zhe Liu, Xiangqian Zhao, Zhiyuan Mao, Li Bai
Artificial Cells, Nanomedicine, and Biotechnology.2019; 47(1): 2246. CrossRef
Combined transarterial chemoembolization and radiotherapy as a first-line treatment for hepatocellular carcinoma with macroscopic vascular invasion: Necessity to subclassify Barcelona Clinic Liver Cancer stage C
Yeon Joo Kim, Jinhong Jung, Ji Hyeon Joo, So Yeon Kim, Jin Hyoung Kim, Young-Suk Lim, Han Chu Lee, Jong Hoon Kim, Sang Min Yoon
Radiotherapy and Oncology.2019; 141: 95. CrossRef
Sorafenib for Recurrent Hepatocellular Carcinoma after Liver Transplantation
Bo Hyun Kim, Joong-Won Park
Journal of Korean Medical Science.2018;[Epub] CrossRef

11,013 View
309 Download
18 Web of Science
16 Crossref

Laparoscopic Assisted Distal Rectal Cancer Resection with Preoperative Concurrent Chemoradiotherapy: Bong Hwa Lee, Mi Young Chang, Sung Kook Park, Taeik Eum, Hyun Joo Shin, Nam Kyu Ro, Chang Nam An, Hae Wan Lee, Lee Su Kim, Hyoung-Chul Park, Hoon Sik Bae, Dae Young Zang, Richard L Whelan; Cancer Res Treat. 2007;39(1):10-15. Published online March 31, 2007; DOI: https://doi.org/10.4143/crt.2007.39.1.10

Abstract PDF PubReader ePub

Purpose

Anatomy of deep pelvis, narrow distal margin and tumor invasion into neighbor organ are obstacles for curative radical resection for advanced cancer of distal rectum. Technically, laparoscopic application after downstaging the tumor with preoperative concurrent chemotherapy (CCRT) may give a solution to overcome the anatomical difficulties. We compared the results of laparoscopic surgery in the patients who received CCRT with those of patients who had conventional surgery.

Materials and Methods

A continuous infusion of 5FU plus leucovorin and radiotherapy (50.4 Gy) in 28 fractions was given each patient as CCRT. They underwent D2 radical resection with TME and ANP for the rectal cancer in 4 weeks.

Results

Thirty three patients had laparoscopic resection such as LAR, colo-anal anastomosis and APR. The results were compared with 12 cases of the conventional resections. As a result of preoperative CCRT, the cancer was down-staged in 71%. Two year disease free survival was 75% and 74% in the group of conventional and laparoscopic resection, respectively (p=0.427). Ileus, voiding difficulty and leakage after surgery were not different between two groups. Weakness of ejaculation was noted in 9~11% of both groups. The DFS of the preoperative CCRT followed by radical resection in the groups with a response was more favorable than that in the group with progressive or stable disease.

Conclusion

Radical resection of advanced distal rectal cancer could be done with performing a laparoscopic assisted operation after CCRT induced down-staging. We may suggest that laparoscopic assisted resection is a good treatment option as it doesn't increase the complications and it has a compatible survival rate to conventional surgery.

Citations

Citations to this article as recorded by

DPYD,TYMS,TYMP,TK1, andTK2Genetic Expressions as Response Markers in Locally Advanced Rectal Cancer Patients Treated with Fluoropyrimidine-Based Chemoradiotherapy
Ming-Yii Huang, Chan-Han Wu, Chun-Ming Huang, Fu-Yen Chung, Ching-Wen Huang, Hsiang-Lin Tsai, Chin-Fan Chen, Shiu-Ru Lin, Jaw-Yuan Wang
BioMed Research International.2013; 2013: 1. CrossRef

10,897 View
48 Download
1 Crossref

Male Breast Cancer: Chung Han Lee, Joong Kyou Kim, Seung Do Lee, Young Hoon Park, Hee Kyoung Chang, Bang Hur, Man Ha Huh; J Korean Cancer Assoc. 1995;27(3):436-442.

Abstract PDF: Male breast cancer is reported to compromise 0.5% of all breast cancers and 0.16% of malignant cancers in men. The histologic patterns of breast cancer in men are similar to those observed in the female breast. We have experienced 9 cases, among 1345 cases, surgically treated breast cancer, from Jan. 1970 to Dec. 1994. The clinical analysis of 9 male breast cancer who had been treated surgically, was done. The results were as follows: 1) In the age distribution, the peak age incidence was 5th decade (56%). 2) The most common symptom and sign was palpable breast mass(78%: 7 cases). 3) The most common duration of symptom, was within lyear(44%: 4cases), 4) In the location and size of tumor, upper quadrant was 56% (5cases) and central: 2 cases, lower outer: icase, multicentric: 1case. T: 4cases T 2cases T,; 1case Tis: 2cases 5) In the operation method, modified radical mastectomy was performed 88%(7cases), wide excision was 12%(2cases) 6) In the pathologic classification, infiltrating ductal carcinoma was 56% (5cases), intraductal carcinoma 2cases, mucinous carcinoma 1cases, papillary carcinoma 1case. 7) In the stage(AJCC, 1988), stage II was 44%(4cases), stage III 2cases, stage I: 1case, stage 0: 2cases 8) In the follow-up 3 patients died after 10 months, 5years, I lyears survival, each cause of death, was recurrence and distant metastasis, sudden aneurysmal rupture, gastrectomy(stomach cancer). other 6 patients are in the disease free state.

2,802 View
12 Download

Cancer of the extrahepatic bile ducts: Dal Cheon Kim, Sung Uhn Baek, Kyung Hyun Choi, Sung Do Lee, Jae Kwan Seo, Jee Kyoung Chang, Man Ha Huh; J Korean Cancer Assoc. 1992;24(6):885-898.

Abstract PDF: No abstract available.

2,337 View
13 Download

Relationship between Expressions of Tumor - Associated Antigen MAGE-3 and p53 Proteins during Cell Cycle by Bivariate Analysis of Flow Cytometry: Hee Kyoung Chang, Deok Jun Kim, Kang Dae Lee, Hwan Jung Roh, G Spagnoli; J Korean Cancer Assoc. 1999;31(4):784-792.

Abstract PDF: PURPOSE
MAGE (melanoma antigen gene) is a tumor associated antigen, presented by HLA class I molecules, which is recognized by cytotoxic T lymphocytes. The expression of MAGE proteins are confined to malignant tumor tissues, except for the normal testis and placental tissues. Therefore, MAGE may be a potential target for immunotherapy of malignant tumors. However, biological aspects associated with the cell cycle are not yet described.
MATERIALS AND METHODS
The material used for this study was a novel human squamous cell carcinoma cell line (PNUH-12) from the hypopharynx, which had one point mutation of 78th base, C to G, in exon 7 of p53 gene. To understand the role of MAGE in relation to cell cycle and its relationship with p53 as the Gl checkpoint regulator, the expressions of MAGE-3 protein and mvtant p53 (Mtp53) were accessed by flow cytometry and immunohistochemistry. Double stains for MAGE-3/Mtp53 was analyzed with bivariate flow cytometry. DNA histograms using MAGE-3/PI (DNA) and Mtp53/PI (DNA) were also analyzed.
RESULTS
The expression rate of MAGE-3 and Mtp53 were 83% and 85%, respectively. MAGE-3 was expressed in cytoplasm, while M:p53 were expressed in the nuclei of the tumor cells on the immunohistochemical sections. With bivariate analyses, coexpression rate of MAGE-3/Mtp53 was 0.96, and MAGE-3 and Mtp53 constantly showed high levels throughout the cell cycle except Go.
CONCLUSIONS
These results mean that (I) MAGE-3 might have yet unknown relationship with mutant p53, (2) expressions of MAGE-3 and Mtp53 are not dependent on the cell cycle in PNUH-12 hypopharyngeal squamous carcinoma cell line, and suggest that MAGE-3 might have a role as important as p53 during the development of malignant tumors.

2,532 View
13 Download

Expression of Rous Sarcoma Virus Enhancer Factor Gene in Human Hepatocellular Carcinoma: Boo Ahn Shin, Kyung Kun Kim, Chol Kyoon Cho, Hyun Chul Lee, Jong Suk Oh, Joon Haeng Rhee, Mee Young Chang; J Korean Cancer Assoc. 1997;29(4):547-554.

Abstract PDF: PURPOSE
We have previously cloned three enhancer factor genes encoding proteins that bind to long terminal repeats (LTRs) of Rous sarcoma virus. Among these genes, RSV- EF-I gene is expressed in rat hepatoma tissues and several proliferating cell lines but not in normal rat liver tissues. We have isolated the human homologue of RSV-EF-I gene and examined its expression in human hepatocellular carcinoma tissues.
MATERIALS AND METHODS
We have screened the human genomic library and cDNA library of Hep G2 cell line derived from human hepatocellular carcinoma to isolate the human homologue of RSV-EF-I gene.
RESULTS
We have isolated one cDNA clone containing about 1.5 kb insert and sequenced. Sequence analysis reveals that this human homologue of RSV-EF-I gene has a high similarities to human YB-1 mRNA, human DNA-binding protein B (dbpB) gene and other Y-box protein genes. It is expressed in human hepatocellular carcinoma but very slightly in normal human liver tissues in Northern blot analysis.
CONCLUSION
Our data suggest that the human homologue of RSV-EF-I gene presumably belongs to Y-box protein family genes and plays a role in the transformation of the human hepatoma cells.

2,788 View
15 Download

Effects of Concurrent Chemoradiotherapy Followed by Surgery in Locoreginal Cancer - preliminary report -: Yun Hae Chang, Sung Bae Kim, Sang Hee Kim, Jong SU Choi, Dae Young Chang, Je Whan Lee, Sang We Kim, Cheolwon Suh, Kyon Hung Lee, Jung Shin Lee, Woo Gyun Kim, Ho Young Song, Hye Sook Chang, Hong Hoon K; J Korean Cancer Assoc. 1996;28(4):690-698.

Abstract PDF: Prognosis of locoregional esophageal cancer treated with conventional surgery or radiotherapy alone has been very poor. In order to improve outcome and determine the efficacy of a combined modality therapy, this prospective study was performed. Between May 1993 and April l995, 44 patients with locoregional esophageal cancer were entered this study. They were treated with 2 courses of 5-FU(DI-5, D30-33) and cisplatin (Dl, D29) plus 48Gy radiation therapy over 4 weeks. 44 patients completed the preoperative reatment. A transhiatal esophagectomy was planned 3~4 weeks after chemoradiotherapy. Clinical response were reevaluable in 43 patients after treatment: 34 patients showed improvement, 5 patients showed stable, 4 patients showed progression. One patient was died of sepsis 1 week after completion of chemotherapy. l8 patients underwent operation after chemoradiation and 9 patients showed complete pathologic response. Grade 3,4 leukopenia and thrombocytopenia were observed in 21% and 7%, respectively. Esophagitis and vomiting were moderate to severe in 43% patients. Median follow-up duration was 7.5months(2-21M), the median survival was not reached. In conclusion, this intensive combined therapy is promising modality with regards to relatively high pathologic complete response rate. Further randomized Jarge scaled study was warrented

2,920 View
15 Download

Case Report

A Case of Angiosarcoma of the Maxillary Sinus: Young Chang Choi, Kun Ho So, Chun Dong Kim, Jeong Rye Kim, Bong Seog Kim; J Korean Cancer Assoc. 1999;31(1):194-200.

Abstract PDF: Angiosarcomas are extremely rare in the nasal cavity and para-nasal sinus. Upto the present only nineteen cases have been reported in the literature. A 31-year-old male presented with right facial swelling and large oral cavity mass. He was treated with wide excision of the tumor by radical maxillectomy. The tumor was diagnosed as angiosarcoma by immunohistochemical staining with factor VIII-reactive antigen. No adjuvant radiotherapy after surgery was done. After 9 montbs from surgery, the tumor recurred in the primary sites of oral cavity and right maxillary sinus and metastasized to the both lungs. He was treated with palliative chemotherapy and showed a stable disease in follow-up magnetic resonance image of para-nasal sinus and simple chest X-ray after second cycle of chemotherapy. He is undergoing further chemotherapy without any problems. We report first in Korea a case of primary angiosarcoma of the right maxillary sinus in a 31-year-old male.

3,116 View
42 Download

Original Article

Study on the malignant Neplasm of Covered People in the Medical Insurance Scheme: Young Chang Kim; J Korean Cancer Assoc. 1984;16(2):324-337.

Abstract PDF: At present, it is fact that study on the Malignant Neoplasm in Korea is confined to clinical reports, survey on the certain hospitals and analysis on the data collecte#d from Cancer Center of National Medical Center. But in these studies, analysis was not made on the medical expenditure and nation-wide data wasn't also presented fully. This study was intended to survey pattern and prevalence of Malignant Neoplasm in Korea. For this, claims having reviewed by the Federation of Korean Medical Insurance Societies during 1983 were analyzed. The major findings were made as follows. 1) The total number claims included in this study was 25.6 million cases, in-patient 6million, out-patient 25 million cases. Among them 79,830(0.3%) cases were Malignant Neoplasm, in-patient 17,833, out-patient 61,997. 2) The total medical expenditure of claims included in this study was 386, 036 million won. Medical expenditure of Malignant Neoplasm was 11,923 million won(3.19%), in-patient 9,466 million won, out-patient 2,457 million won. 3) The frequeney orders of Malignant Neoplasm was, in the case of out-patient, stomach, cervix uteri, trachea-bronchus and lung, female breast, rectum and anus. In the case of in-panti ent, stomach, liver and intraheptic bile ducts, trachea-bronchus and lung, cervix uteri, leukaemia. 4) The frequency orders of Malignant Neoplasm, in the case of male, is stomach, liver and intrahepatic bile ducts, trachea-bronchus and lung, leukaemia, rectum and anus. In the case of female, cervix uteri, stomach, breast, liver and intrahepatic bile ducts, trachea-bronchus and lung. 5) Medical expeuditure per out-patient Malignant Neoplasm ca".e was higher than that of other out-patient caze by 3. 8 times, in case of expenditure per day, by 3 times. 6) The highest expensive medical expenditure per case was in the case of out-patient, nasopharynx, and in the case of in-patient, brain. 7) The orders af age group distribution, in case of in-partient, was 50-59 years 30.7ii, 60-69 years 27.0%, 40-49 Years 18. 6%(male), 50-59 years 25. Bl, 40-49 years 25.3% 60-69 years 15.3%(female). 8) Medical care utilization rate of Malignant Neoplosm for in-patient was 198/100,000 (male), 159/100, 000(female) and 178/100, 000(total). 9) Annual rate of incidences of Malignant Neoplasm has heen increased gradually: 2.39% (1981), 2.40%(1982), L94%(1988). There is statistical aignificant different by year and diseases, 10) The utilization rate of medical care institution was general hospital 91.1% hospital 7 0 % clinic 1. 9%. Analysis of Malignant Neoplasm and registration of cancer patients will be developed with making use of claims reviewed. Resident registration number and start day of treatment on the eleims makes it possible.

2,795 View
13 Download

First
Prev
Page of 1
Next
Last

Search